MX2014014813A - Uso de agonistas o antagonistas inversos para el receptor de grelina para tratar trastornos del sueño. - Google Patents
Uso de agonistas o antagonistas inversos para el receptor de grelina para tratar trastornos del sueño.Info
- Publication number
- MX2014014813A MX2014014813A MX2014014813A MX2014014813A MX2014014813A MX 2014014813 A MX2014014813 A MX 2014014813A MX 2014014813 A MX2014014813 A MX 2014014813A MX 2014014813 A MX2014014813 A MX 2014014813A MX 2014014813 A MX2014014813 A MX 2014014813A
- Authority
- MX
- Mexico
- Prior art keywords
- sleep disorders
- ghrelin receptor
- treating sleep
- receptor inverse
- antagonists
- Prior art date
Links
- 102000000393 Ghrelin Receptors Human genes 0.000 title abstract 3
- 108010016122 Ghrelin Receptors Proteins 0.000 title abstract 3
- 239000002464 receptor antagonist Substances 0.000 title abstract 3
- 239000002469 receptor inverse agonist Substances 0.000 title abstract 3
- 208000019116 sleep disease Diseases 0.000 title abstract 3
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261655177P | 2012-06-04 | 2012-06-04 | |
| US201361812416P | 2013-04-16 | 2013-04-16 | |
| PCT/IB2013/054177 WO2013182933A1 (en) | 2012-06-04 | 2013-05-21 | Use of ghrelin receptor inverse agonists or antagonists for treating sleep disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2014014813A true MX2014014813A (es) | 2015-02-12 |
Family
ID=48700662
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014014813A MX2014014813A (es) | 2012-06-04 | 2013-05-21 | Uso de agonistas o antagonistas inversos para el receptor de grelina para tratar trastornos del sueño. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9370516B2 (enExample) |
| EP (1) | EP2854856B1 (enExample) |
| JP (1) | JP6165852B2 (enExample) |
| KR (1) | KR101708989B1 (enExample) |
| CN (1) | CN104334193A (enExample) |
| AU (1) | AU2013273263B2 (enExample) |
| BR (1) | BR112014029577A2 (enExample) |
| CA (1) | CA2874196C (enExample) |
| ES (1) | ES2716303T3 (enExample) |
| HK (1) | HK1202459A1 (enExample) |
| IL (1) | IL235883A0 (enExample) |
| MX (1) | MX2014014813A (enExample) |
| RU (1) | RU2600895C2 (enExample) |
| SG (1) | SG11201407387UA (enExample) |
| WO (1) | WO2013182933A1 (enExample) |
| ZA (1) | ZA201408672B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105175272A (zh) * | 2015-08-31 | 2015-12-23 | 吴玲 | 制备r-5-溴-1-氨基茚满的方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9606805D0 (en) | 1996-03-30 | 1996-06-05 | Glaxo Wellcome Inc | Medicaments |
| US6414002B1 (en) | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
| WO2004058160A2 (en) * | 2002-12-20 | 2004-07-15 | The Mclean Hospital Corporation | Compounds for the normalization of the sleep/wake cycle |
| US20050171132A1 (en) * | 2003-09-26 | 2005-08-04 | Zhili Xin | Diaminopyrimidine derivatives as selective growth hormone secrectgogue receptor (GHS-R) antagonists |
| JP2007537207A (ja) * | 2004-05-14 | 2007-12-20 | ノボ ノルディスク アクティーゼルスカブ | 一定の中枢神経疾患の治療のためのグレリンアンタゴニストの使用 |
| US20090253673A1 (en) * | 2006-07-12 | 2009-10-08 | Min Ge | Substituted Pyrazoles as Ghrelin Receptor Antagonists |
| US8309530B2 (en) * | 2009-02-04 | 2012-11-13 | Washington State University | Compositions and methods for modulating ghrelin-mediated conditions |
| ES2557895T3 (es) * | 2010-03-19 | 2016-01-29 | Pfizer Inc | Derivados de 2,3-dihidro-1H-inden-1-il-2,7-diazaespiro[3.6]nonano y su uso como antagonistas o agonistas inversos del receptor de grelina |
-
2013
- 2013-05-21 JP JP2015515606A patent/JP6165852B2/ja not_active Expired - Fee Related
- 2013-05-21 WO PCT/IB2013/054177 patent/WO2013182933A1/en not_active Ceased
- 2013-05-21 ES ES13732257T patent/ES2716303T3/es active Active
- 2013-05-21 HK HK15103243.2A patent/HK1202459A1/xx unknown
- 2013-05-21 BR BR112014029577A patent/BR112014029577A2/pt active Search and Examination
- 2013-05-21 RU RU2014146109/15A patent/RU2600895C2/ru not_active IP Right Cessation
- 2013-05-21 US US14/398,800 patent/US9370516B2/en active Active
- 2013-05-21 SG SG11201407387UA patent/SG11201407387UA/en unknown
- 2013-05-21 CA CA2874196A patent/CA2874196C/en not_active Expired - Fee Related
- 2013-05-21 EP EP13732257.4A patent/EP2854856B1/en not_active Not-in-force
- 2013-05-21 MX MX2014014813A patent/MX2014014813A/es unknown
- 2013-05-21 CN CN201380029429.7A patent/CN104334193A/zh active Pending
- 2013-05-21 KR KR1020147034009A patent/KR101708989B1/ko not_active Expired - Fee Related
- 2013-05-21 AU AU2013273263A patent/AU2013273263B2/en not_active Ceased
-
2014
- 2014-11-24 IL IL235883A patent/IL235883A0/en unknown
- 2014-11-25 ZA ZA2014/08672A patent/ZA201408672B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150013236A (ko) | 2015-02-04 |
| US9370516B2 (en) | 2016-06-21 |
| AU2013273263A1 (en) | 2014-11-27 |
| EP2854856B1 (en) | 2019-01-23 |
| JP2015518876A (ja) | 2015-07-06 |
| US20150119381A1 (en) | 2015-04-30 |
| HK1202459A1 (en) | 2015-10-02 |
| CA2874196A1 (en) | 2013-12-12 |
| WO2013182933A1 (en) | 2013-12-12 |
| AU2013273263B2 (en) | 2017-08-24 |
| RU2600895C2 (ru) | 2016-10-27 |
| CN104334193A (zh) | 2015-02-04 |
| ZA201408672B (en) | 2016-09-28 |
| CA2874196C (en) | 2016-12-06 |
| KR101708989B1 (ko) | 2017-02-21 |
| JP6165852B2 (ja) | 2017-07-19 |
| SG11201407387UA (en) | 2014-12-30 |
| ES2716303T3 (es) | 2019-06-11 |
| IL235883A0 (en) | 2015-01-29 |
| EP2854856A1 (en) | 2015-04-08 |
| RU2014146109A (ru) | 2016-07-27 |
| BR112014029577A2 (pt) | 2017-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015501595A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| EA201390977A1 (ru) | Комбинация агониста опиоидных рецепторов и антагониста опиоидных рецепторов для лечения болезни паркинсона | |
| PH12015501598A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| MY188450A (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| PH12015501600A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| JO3078B1 (ar) | مورفولينوثيازولات بصفتها منظمات الوستيرية نوع الفا 7 موجبة | |
| MX371344B (es) | Antagonistas de il-4r para usarse en el tratamiento o prevención de asma persistente y asma severa. | |
| MX369576B (es) | Imidazoles 2-piridilo sustituidos como inhibidores de alk5 y/o alk4. | |
| PH12015501596A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| GEP20186839B (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
| MX2013013786A (es) | Compuestos con actividad antagonista de los receptores muscarinicos y actividad agonista del receptor beta2 adrenergico. | |
| WO2014066799A3 (en) | Modulators of resistant androgen receptor | |
| MX369518B (es) | Combinacion de inhibidor de p13k e inhibidor de c-met. | |
| PH12017501424A1 (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
| IL230487B (en) | 6-(n-(7-chloro-1-hydroxy-3,1-dihydrobenzo[c][1,2]oxaborole-5-yl)methylsulfonamido)-5-cyclopropyl-2-(4-fluorophenyl)-n- Methylbenzofuran-3-carboxamide, their salts and pharmaceutical preparations containing them | |
| MX345656B (es) | (piridin-4-il)bencilamidas como moduladores alostericos de nachr alfa 7. | |
| MX2024013184A (es) | Metodos y composiciones para tratar apnea del sue?o | |
| PH12014501390A1 (en) | Novel therapeutic use of p75 receptor antagonists | |
| BR112014029577A2 (pt) | uso de agonistas ou antagonistas inversos do receptor de grelina para tratamento de transtornos do sono | |
| IN2014DN09359A (enExample) | ||
| TN2013000429A1 (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
| MX2019009243A (es) | Antagonistas il-4r para usarse en el tratamiento o previncion de asma persistente y asma severa. | |
| UA82584U (ru) | Способ лечения вестибулярной мигрени и коморбидного синдрома головокружения у женщин с вестибулярной дисфункцией в перименопаузальном периоде |